Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw unusually-high trading volume on Friday . Approximately 201,869 shares changed hands during mid-day trading, an increase of 166% from the previous session’s volume of 75,912 shares.The stock last traded at $38.15 and had previously closed at $38.17.

Analyst Upgrades and Downgrades

Several brokerages have commented on NBTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Leerink Partners increased their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Finally, UBS Group lifted their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and an average target price of $37.33.

Nanobiotix Stock Performance

The stock has a 50 day simple moving average of $37.82 and a 200-day simple moving average of $34.62.

Hedge Funds Weigh In On Nanobiotix

Several institutional investors and hedge funds have recently modified their holdings of NBTX. Millennium Management LLC bought a new position in Nanobiotix in the 4th quarter worth about $390,000. Marshall Wace LLP purchased a new stake in Nanobiotix during the 4th quarter valued at about $220,000. Finally, Royal Bank of Canada increased its stake in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.